Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Dose Olodaterol in COPD
NCT01809262Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2005
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olodaterol in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Forced Expiratory Volume in One Second. Started Dec 2005; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01809262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01809262.